Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease.
Advanced non-small cell lung cancer (advanced NSCLC)
chronic obstructive pulmonary disease (COPD)
first-line chemotherapy
negative driver mutation
poor performance status (poor PS)
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
24
09
2020
accepted:
11
06
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
ppublish
Résumé
Patients with non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD) with poor performance status (PS) are common in clinical practice with few related studies. Present studies have found that weekly low-dose docetaxel or gemcitabine combined with platinum is suitable for elderly or poor PS patients with advanced NSCLC. Untreated advanced driver mutation-negative NSCLC patients with COPD and PS ≥2 were enrolled in this double-blind randomized trial. Both groups controlled their COPD symptoms according to the GOLD guidelines. The anti-tumor regimens included docetaxel (37.5 mg/m Among the 52 patients (DC, n=25; GC, n=27), the median follow-up time was 12.3 months. There was no significant difference in tumor overall response rate (ORR; DC, 20.0% Weekly low-dose docetaxel or gemcitabine combined with carboplatin chemotherapy regimens can yield survival benefits and a tolerable safety profile in patients with driver mutation-negative advanced NSCLC and poor PS complicated with COPD, with no significant difference between the two regimens. Chinese Clinical Trial Registry ChiCTR-IPR-15006164.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD) with poor performance status (PS) are common in clinical practice with few related studies. Present studies have found that weekly low-dose docetaxel or gemcitabine combined with platinum is suitable for elderly or poor PS patients with advanced NSCLC.
METHODS
METHODS
Untreated advanced driver mutation-negative NSCLC patients with COPD and PS ≥2 were enrolled in this double-blind randomized trial. Both groups controlled their COPD symptoms according to the GOLD guidelines. The anti-tumor regimens included docetaxel (37.5 mg/m
RESULTS
RESULTS
Among the 52 patients (DC, n=25; GC, n=27), the median follow-up time was 12.3 months. There was no significant difference in tumor overall response rate (ORR; DC, 20.0%
CONCLUSIONS
CONCLUSIONS
Weekly low-dose docetaxel or gemcitabine combined with carboplatin chemotherapy regimens can yield survival benefits and a tolerable safety profile in patients with driver mutation-negative advanced NSCLC and poor PS complicated with COPD, with no significant difference between the two regimens.
TRIAL REGISTRATION
BACKGROUND
Chinese Clinical Trial Registry ChiCTR-IPR-15006164.
Identifiants
pubmed: 34295663
doi: 10.21037/tlcr-21-371
pii: tlcr-10-06-2573
pmc: PMC8264331
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2573-2587Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tlcr-21-371). The authors have no conflicts of interest to declare.
Références
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
BMC Cancer. 2018 Oct 29;18(1):1053
pubmed: 30373585
Ann Oncol. 2004 Jan;15(1):45-50
pubmed: 14679118
Clin Lung Cancer. 2011 Sep;12(5):272-9
pubmed: 21704567
Ai Zheng. 2005 Aug;24(8):985-9
pubmed: 16086878
Int J Oncol. 2016 Jan;48(1):13-27
pubmed: 26530033
J Clin Oncol. 2005 Nov 20;23(33):8389-95
pubmed: 16293869
Eur Respir J. 2009 Aug;34(2):380-6
pubmed: 19196816
Chest. 2006 May;129(5):1305-12
pubmed: 16685023
Respirology. 2016 Feb;21(2):269-79
pubmed: 26567533
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
PLoS One. 2015 Nov 10;10(11):e0142306
pubmed: 26555338
Ann Oncol. 2010 Apr;21(4):795-799
pubmed: 19815651
J Thorac Oncol. 2014 Jun;9(6):812-7
pubmed: 24807154
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
Front Oncol. 2018 Jul 24;8:253
pubmed: 30087850
Zhonghua Jie He He Hu Xi Za Zhi. 2020 May 12;43(5):450-454
pubmed: 32450634
J Clin Oncol. 2013 Aug 10;31(23):2849-53
pubmed: 23775961
J Thorac Dis. 2017 Dec;9(12):E1110-E1117
pubmed: 29312776
Cochrane Database Syst Rev. 2010 May 12;(5):CD007309
pubmed: 20464750
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Lung Cancer. 2006 Feb;51(2):237-43
pubmed: 16378657
Ann Oncol. 2002 Jan;13(1):12-5
pubmed: 11863092
Zhonghua Zhong Liu Za Zhi. 2017 Nov 23;39(11):855-861
pubmed: 29151293
Lung Cancer. 2007 Jul;57(1):72-8
pubmed: 17391803
Int J Chron Obstruct Pulmon Dis. 2017 Dec 11;12:3541-3547
pubmed: 29270008
Am J Respir Crit Care Med. 2007 Apr 1;175(7):636-7
pubmed: 17384324
Int J Chron Obstruct Pulmon Dis. 2019 May 01;14:929-938
pubmed: 31118602
J Clin Oncol. 2000 Jul;18(13):2529-36
pubmed: 10893283
Cancer Chemother Pharmacol. 2017 May;79(5):873-880
pubmed: 28341958
Ann Thorac Surg. 2007 Sep;84(3):946-50
pubmed: 17720404
Int J Chron Obstruct Pulmon Dis. 2018 Jul 12;13:2139-2146
pubmed: 30034229
Lung Cancer. 2015 Sep;89(3):274-9
pubmed: 26143106
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Korean Med Sci. 2008 Dec;23(6):992-8
pubmed: 19119442
Lancet Oncol. 2012 Nov;13(11):1161-70
pubmed: 23078958
Prim Care Respir J. 2010 Mar;19(1):57-61
pubmed: 19756330
Lung Cancer. 2013 Jul;81(1):77-83
pubmed: 23643177
Ai Zheng. 2006 Aug;25(8):990-4
pubmed: 16965680
J Clin Oncol. 2005 Jan 1;23(1):190-6
pubmed: 15625373
Int J Chron Obstruct Pulmon Dis. 2018 Nov 21;13:3805-3812
pubmed: 30538442